{"filing":{"accession_number":"0001213900-26-077775","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-07-14","report_date":null,"primary_document":"ea0297933-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026077775/ea0297933-6k_canfite.htm"},"events":[{"id":17732,"run_id":15897,"accession_number":"0001213900-26-077775","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The press release announces the Australian Patent Office's allowance of Patent Application No. 2021290439 for \"Treatment of Advanced Metastatic Cancer,\" which strengthens Can-Fite's intellectual property portfolio for Namodenoson in hepatocellular carcinoma and pancreatic cancer. This is a material operational/strategic milestone that extends patent protection in a major international market and supports the company's most advanced oncology programs, but it does not fit the specific event categories of earnings release, M\u0026A activity, executive changes, or other defined types. The patent allowance is a significant development for a clinical-stage biotech company's pipeline protection and market exclusivity.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-07-14","form":"6-K","submitted_at":null,"items":[{"id":16315,"accession_number":"0001213900-26-077775","item_number":"EX-99.1","item_title":"ea029793301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces the Australian Patent Office's allowance of Patent Application No. 2021290439 for \"Treatment of Advanced Metastatic Cancer,\" which strengthens Can-Fite's intellectual property portfolio for Namodenoson in hepatocellular carcinoma and pancreatic cancer. This is a material operational/strategic milestone that extends patent protection in a major international market and supports the company's most advanced oncology programs, but it does not fit the specific event categories of earnings release, M\u0026A activity, executive changes, or other defined types. The patent allowance is a significant development for a clinical-stage biotech company's pipeline protection and market exclusivity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:12:38.259688+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16315,"accession_number":"0001213900-26-077775","item_number":"EX-99.1","item_title":"ea029793301ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The press release announces the Australian Patent Office's allowance of Patent Application No. 2021290439 for \"Treatment of Advanced Metastatic Cancer,\" which strengthens Can-Fite's intellectual property portfolio for Namodenoson in hepatocellular carcinoma and pancreatic cancer. This is a material operational/strategic milestone that extends patent protection in a major international market and supports the company's most advanced oncology programs, but it does not fit the specific event categories of earnings release, M\u0026A activity, executive changes, or other defined types. The patent allowance is a significant development for a clinical-stage biotech company's pipeline protection and market exclusivity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:12:38.259688+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-07-14"}]}